2018-10-15| IPOR&D

Tracking “OFF THE SHELF” CAR-T Cell therapy & an IPO worth $100M

by GeneOnline
Share To

By Ajay V. Patil

With whopping $300 million in series-A funding, Allogene therapeutics quickly raised additional $100 million to become a blockbuster biotech IPO. We summarize its inception and development of next generation allogenic CAR-T cell therapy in tandem.

Arie Belldegrun and David Chang led Kite Pharma, which developed one of the initial FDA approved engineered autologous CAR-T cell therapies. Gilead Sciences took over Kite Pharma for $11.9 billion in an all-cash deal. Early versions showed that complex manufacturing of on-demand autologous CAR-T cells is both, time consuming and expensive. Hence, development of allogenic CAR-T cells is considered as a key to make the CAR-T cell therapy more accessible. The company which first started developing in this direction and ultimately produced allogenic UCART19 using TALEN technology was Cellectis. UCART19 was acquired by Pfizer – focusing to develop a portfolio of 16 preclinical cell therapy assets. Arie Belldegrun and David Chang, started Allogene Therapeutics with $300 million in Series A funds and acquired Pfizer’s cell therapy portfolio in return for 25 percent ownership stake.

For the near future goals, Allogene plans to move UCART19, CD19-targeting CAR-T treatment into registrational trials by late half of 2019. It is currently in phase 1 trials for children and adults with acute lymphoblastic leukemia (ALL). Other products in development include, ALLO-715, ALLO-819, and ALLO-501. They also plan is to submit INDs for ALLO-715 and ALLO-501 by next year. These CART therapies mainly target two proven candidates – CD19 and BCMA. However, there are three new targets in the development pipeline (Flt3, CD70 and DLL3).

Assuring company’s faith in assets and top executives, CFO Eric Schmidt quoted, “I think we at Allogene have been very fortunate to have inherited assets that make for an exciting story in an exciting area of therapeutic development in the CAR-T space. We have on our side Arie Belldegrun and David Chang; those are guys who have been here before, know the business, know the landscape and know the people. I don’t think there are too many teams that can claim to have the experience that we have.”

The fate of this company is crucial for the development of next generation CAR-T cell therapy in general and for the fate of clinical adoption of allogenic immunotherapies in particular. Although company is going through appropriate transitions and being meticulously grown by experienced team, successful phase II & III clinical trial results of its early products will boost the further growth and expansion towards larger and more promising portfolio.


  3. Allogene Therapeutics S-1 Breakdown – Nisarg Patel



© All rights reserved. Collaborate with us: [email protected]
Related Post
STLI Webinar Series 1: Experts Discuss Regulatory Trends in Regenerative Medicine
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top